U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Diagnostic genetic testing : core concepts and the wider context for human DNA analysis

Bourn, David.

Cham, Switzerland : Springer, [2022]

NLM ID:
9918697378106676
[Book]
2.

Pediatric nephropathology & childhood kidney tumors

Liapis, Helen.

Cambridge, United Kingdom ; New York, NY : Cambridge University Press, 2022.

NLM ID:
9918351487506676
[Book]
3.

Translational strategies for autosomal recessive and dominant polycystic kidney disease

Germino, Gregory G; Guay-Woodford, Lisa M; National Institutes of Health (US) Clinical Center.

[Bethesda, Md.] : [National Institutes of Health], [2021]

NLM ID:
9918230800806676
[Remote electronic resource, Videorecording]
4.

Cystic fibrosis : a multi-organ system approach

Davis, Stephanie D; Rosenfeld, Margaret; Chmiel, James; American Thoracic Society.

Cham, Switzerland : Humana Press : American Thoracic Society, [2020]

NLM ID:
101774145
[Book]
5.

Medical genetics

Jorde, Lynn B; Carey, John C, 1946-; Bamshad, Michael J.

Sixth edition.
Philadelphia, PA : Elsevier, [2020]

NLM ID:
101767678
[Book]
6.

Modulator treatments for cystic fibrosis : effectiveness and value

Tice, Jeffrey A; Chapman, Rick M; Seidner, Matt; Pearson, Steven D; Rind, David M; Institute for Clinical and Economic Review.

[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 27, 2020.

NLM ID:
101769589
[Electronic Resource]
7.

Nusinersen for adolescents and adults with spinal muscular atrophy : a review of clinical effectiveness

Janoudi, Ghayath; McCormack, Suzanne, (Research information specialist); Canadian Agency for Drugs and Technologies in Health.

Version: 1.0.
Ottawa : Canadian Agency for Drugs and Technologies in Health, September 10, 2020.

NLM ID:
101776267
[Electronic Resource]
8.

Pharmacoeconomic review report (resubmission). Nusinersen (Spinraza) (Biogen Canada Inc.) : indication : treatment of patients with 5q spinal muscular atrophy.

Canadian Agency for Drugs and Technologies in Health.

Final (with redactions)
Ottawa (ON) : CADTH, April 2019.

NLM ID:
101750616
[Electronic Resource]
9.

Clinical review report. Nitisinone (Nitisinone tablets) (Cycle pharmaceuticals ltd.).

Canadian Agency for Drugs and Technologies in Health.

Version: Final.
Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, August 2018.

NLM ID:
101747317
[Electronic Resource]
10.

Clinical review report. Nusinersen (Spinraza) (Biogen Canada Inc.).

Canadian Agency for Drugs and Technologies in Health.

Version 1.0.
Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, January 2018.

NLM ID:
101739209
[Electronic Resource]
11.

Nitisinone (MDK-nitisinone) : (MendeliKABS inc.) : indication : for the treatment of patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Canadian Agency for Drugs and Technologies in Health.

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, April 2018.

NLM ID:
101739103
[Electronic Resource]
12.

Nitisinone (Orfadin) (Sobi Canada Inc.).

Canadian Agency for Drugs and Technologies in Health.

Ottawa (ON) : CADTH, April 2018.

NLM ID:
101739163
[Electronic Resource]
13.

Pharmacoeconomic review report. Cysteamine delayed-release capsules (Procysbi), Horizon Pharma Ireland Ltd.

Canadian Agency for Drugs and Technologies in Health.

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, February 2018.

NLM ID:
101740815
[Electronic Resource]
14.

Pharmacoeconomic review report. Nusinersen (Spinraza) (Biogen Canada Inc.).

Canadian Agency for Drugs and Technologies in Health.

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, January 2018.

NLM ID:
101739394
[Electronic Resource]
15.

Retinal degenerative diseases : mechanisms and experimental therapy

Ash, John D; Anderson, Robert E (Robert Eugene); LaVail, Matthew M; Rickman, Catherine Bowes; Hollyfield, Joe G; Grimm, Christian, 1962-; International Symposium on Retinal Degenerations (17th 2016 Kyoto Japan).

Cham, Switzerland : Springer, [2018]

NLM ID:
101730690
[Book]
16.

Case studies in movement disorders : common and uncommon presentations

Bhatia, Kailash; Erro, Roberto; Stamelou, Maria.

Cambridge, United Kingdom ; New York, NY : Cambridge University Press, 2017.

NLM ID:
101711537
[Book]
17.

Medical genetics

Jorde, Lynn B; Carey, John C, 1946-; Bamshad, Michael J.

Fifth edition.
Philadelphia, PA : Elsevier, [2016]

NLM ID:
101658517
[Book]
18.

Ivacaftor (Kalydeco) 150 mg tablet : for treatment of cystic fibrosis with G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or G970R mutation.

Canadian Agency for Drugs and Technologies in Health.

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2015 Jul.

NLM ID:
101680375
[Electronic Resource]
19.

Primary immunodeficiency disorders : a historic and scientific perspective

Etzioni, Amos; Ochs, Hans D, 1936-.

Oxford : Elsevier Academic Press, [2014]

NLM ID:
101644998
[Book]
20.

Epithelial cell culture protocols

Randell, Scott H; Fulcher, M Leslie.

2nd ed.
New York : Humana Press ; Springer, c2012.

NLM ID:
101598009
[Book]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...